Reducing Cost of Capital
Transforming Biotech Financing: The Impact of R&D Tax Refund Financing on Cost of Capital and Enterprise Value.
To download our whitepaper please click here >>
About the whitepaper
Through a detailed discussion of these financial principles, this paper enables readers to understand the integral role that R&D financing plays in enhancing cost structures and overall valuations for biotech
companies. Ultimately, the integration of R&D tax refund financing into the funding landscape not only strengthens the financial foundations of these firms but also amplifies their enterprise value, supporting sustainability and innovation within Australia’s biotechnology sector.
About Endpoints Capital
Endpoints Capital is an Australian-based R&D finance firm that specialises in providing financing solutions for biotechnology companies accessing the Australian Research & Development Tax Incentive program. Endpoints’ mission is to address the funding challenges faced by biotechs, allowing them to focus on innovation and development. As an Australian private company with 30 years of life sciences experience, Endpoints Capital is playing a crucial role in supporting the growth of the biotech industry in Australia.
